Drug intelligence / Profile preview

ABVIRO

Development stage: Preclinical
Lead developer: AbViro
Modality: Small Molecules
Administration: Oral

Overview

ABVIRO is a program of small molecule antiviral agents developed by Agastiya Biotech for the treatment of COVID-19 and Dengue. The lead compound, AB001, is an orally bioavailable multi-targeted small molecule that was originally developed for oncology. In the context of viral infections, it acts by binding to the Angiotensin-Converting Enzyme 2 (ACE2) receptor to block viral entry and inhibiting the non-structural protein 15 (NSP15) endoribonuclease to prevent viral replication. Preclinical studies have demonstrated in vitro activity against SARS-CoV-2 with minimal toxicity.

Targets

Nsp15 (SARS-CoV-2 non-structural protein 15)ACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on ABVIRO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABVIRO.

Explore the full profile